Fig. 4. Activation of AP3 expression by LFY in vivo. (A) Results from real time RT-PCR amplification of RNA isolated from 35S::LFY-GR; 35S::UFO seedlings mock treated with 0.1% ethanol and 0.015% Silwet (M), or treated with dexamethasone (D), cycloheximide (C), or dexamethasone and cycloheximide together (D/C). Amplifications were carried out with primers and probe corresponding to AP3, and normalized to the mock-treated control. Standard deviations are indicated. (B) Results from real time RT-PCR amplification of 35S::LFY-GR; 35S::UFO seedling RNA using primers and probe corresponding to AP1; treatments and labels as in A. (C) Results from real time RT- PCR amplification of seedling RNA from the indicated genotypes, using primers and probe corresponding to AP3. Standard deviations are indicated. (D) Results from real time RT-PCR amplification of 35S::LFY-GR; lfy-6/lfy-6 young floral tissue RNA using primers and probe corresponding to AP3; treatments and labels as in part (A). (E) Results from real time RT-PCR amplification of 35S::LFY-GR; lfy-6/lfy-6 young floral tissue RNA using primers corresponding to AP1; treatments and labels as in A. (F) Results from RT-PCR amplification of 35S::LFY-GR; ap1-1/ap1-1 young floral tissue RNA using primers and probe corresponding to AP3; treatments and labels as in A.
